Literature DB >> 16424737

Recombinant activated protein C: decisions for administration.

R Phillip Dellinger1.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16424737     DOI： 10.1097/01.ccm.0000199068.67569.b3

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  4 in total

1.  Current treatment of severe sepsis.

Authors:  Ismail Cinel; R Phillip Dellinger
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

Review 2.  [PROWESS, ENHANCE and ADDRESS: clinical implications for the treatment with drotrecogin alfa (activated)].

Authors:  M Cobas Meyer; H Langenfeld; R Rossaint; A Sablotzki
Journal:  Anaesthesist       Date:  2006-06       Impact factor: 1.041

3.  Reversal of refractory septic shock with drotrecogin alpha (activated).

Authors:  A Vieillard-Baron; V Caille; C Charron; G Belliard; P Aegerter; B Page; F Jardin
Journal:  Intensive Care Med       Date:  2009-06-16       Impact factor: 17.440

4.  Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis.

Authors:  Vania Costa; James M Brophy
Journal:  BMC Anesthesiol       Date:  2007-06-25       Impact factor: 2.217
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.